Business Context and Reporting Period
This Form 8-K was filed by TenX Keane Acquisition (the "Company") on April 26, 2024. The Company is a Cayman Islands-based special purpose acquisition company (SPAC) and an emerging growth company. The filing reports on the extension of the deadline to consummate a business combination with Citius Oncology, Inc. (via Citius Pharmaceuticals, Inc.), as previously disclosed in a Merger Agreement dated October 23, 2023.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The specific financial activity reported is as follows:
- Extension Contribution: $66,667 deposited into the Company's trust account by Citius Pharma (the Sponsor's designee).
- Debt Obligation: The Company issued an unsecured, non-interest-bearing promissory note in the principal amount of $66,667 to Citius Pharma.
- Liquidity: The filing does not provide a clear value for total cash or liquidity outside of the specific trust account deposit.
Material Changes
The primary material change is the extension of the business combination deadline. Originally set to expire on April 18, 2024, the deadline has been extended by one month to May 18, 2024. This extension was executed pursuant to the Company's Charter, which allows for up to seven one-month extensions upon payment of $66,667 (or $0.03 per public share, whichever is lesser) per month.
Outlook, Risks, and Management Commentary
Outlook: The Company is actively pursuing the merger with Citius Oncology. The extension provides an additional month to finalize the transaction.
Contingencies: The repayment of the $66,667 promissory note is contingent upon the terms of the Merger Agreement. The note bears no interest.
Risks: The filing implies the risk of failing to consummate the business combination by the new deadline of May 18, 2024, which could result in liquidation if no further extensions are granted or the deal is not completed.
Investor Verification Checklist
- Verify the status of the Merger Agreement between TenX Keane Acquisition and Citius Oncology, Inc.
- Confirm the terms of the unsecured promissory note (Exhibit 10.1) regarding repayment conditions upon deal completion or termination.
- Monitor whether the Company will utilize additional extension options available under its Charter beyond the current May 18, 2024 deadline.
- Check for any subsequent filings regarding shareholder approval or regulatory clearance for the proposed business combination.